Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19280729 | 0.84 | AR (0.69) | ARCYP19A1ALDH1A1MAOBHPGD | |
| SCHEMBL9502758 | 0.82 | ALDH1A1 (0.48) | ARCYP19A1IMPDH2IMPDH1ALDH1A1 | |
| SCHEMBL27579557 | 0.81 | AR (0.42) | ARIMPDH2IMPDH1SMN1; SMN2 | |
| SCHEMBL9710755 | 0.80 | CYP11B1 (0.49) | ARCYP19A1SMN1; SMN2PDE4B | |
| SCHEMBL1940627 | 0.79 | AR (0.57) | ARCYP19A1ALDH1A1MAOBHPGD | |
| SCHEMBL23795061 | 0.76 | AR (0.55) | ARCYP19A1ALDH1A1MAOBHPGD | |
| SCHEMBL23795084 | 0.76 | CYP19A1 (0.50) | ARCYP19A1ALDH1A1MAOBHPGD | |
| SCHEMBL23795062 | 0.76 | AR (0.55) | ARCYP19A1 | |
| SCHEMBL23795081 | 0.76 | AR (0.51) | ARCYP19A1ALDH1A1MAOBHPGD | |
| SCHEMBL13327517 | 0.75 | AR (0.53) | ARCYP19A1ALDH1A1MAOBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521340-A1 | A PHTHALONITRILE MONOMER MODIFIED BY ORGANOPHOSPHATE FRAGMENTS, A METHOD FOR OBTAINING SAME, A BINDER BASED THEREON, AND A PREPREG | Joint Stock Company Scientific and Production Association "Unichimtek" (JSC PSA "Unichimtek) (RU) | 2019-08-07 | — | — | EP | disclosed |
| US-20190218235-A1 | Phthalonitrile Monomer Modified with Organophosphorus Fragments, a Method of Producing thereof, a Binder Based Thereon, and a Prepreg | JOINT STOCK COMPANY SCIENTIFIC AND PRODUCTION ASSOCIATION "UNICHIMTEK" (JSC PSA "UNICHIMTEK") (RU) | 2019-07-18 | — | — | US | disclosed |
| EP-3211023-A1 | PHTHALONITRILE MONOMER MODIFIED WITH ORGANOSILICON FRAGMENTS | Joint Stock Company Scientific and Production Association "Unichimtek" (JSC PSA "Unichimtek) (RU) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218235-A1 | Phthalonitrile Monomer Modified with Organophosphorus Fragments, a Method of Producing thereof, a Binder Based Thereon, and a Prepreg | THEM6, NOTUM, PNN | AR 2119/4885CYP19A1 1229/4885IMPDH2 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.